Cabot (CBT) Stock: Buy, Sell, or Hold?
CBT - Cabot Corporation
$74.33
0.55 (0.75%)
▲
5d:
-1.52%
30d:
-5.67%
90d:
-17.55%
BUY
HIGH Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 02, 2026
9d
Get Alerted When CBT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CBT shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: CBT shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$107.92
Based on 6.8% avg growth
INTRINSIC VALUE TODAY
$67.01
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CBT is currently trading at $74.33, which is considered oversold relative to its 30-day fair value range of $74.69 to $78.58. The stock's valuation (Forward PE: 10.6) is in line with its historical norms (11.1). Remarkably, the market is currently pricing in an annual earnings decline of 1.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CBT is in a strong downtrend. The price is currently testing key support at $72.62. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CBT scores 71/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $90.33 (+21.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CBT is in a strong downtrend. The price is currently testing key support at $72.62. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CBT scores 71/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $90.33 (+21.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$74.69 -
$78.58
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (71/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 21.5% below Wall St target ($90.33)
- BULLISH: Bottoming setup score 71/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$74.69 -
$78.58
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$72.62
Resistance Level
$76.65
Current Trend
Strong Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.64
Wall Street Target
$90.33
(+21.5%)
Revenue Growth (YoY)
6.4%
Earnings Growth (YoY)
-93.7%
Profit Margin
5.2%
Valuation Discount vs History
-1.5% cheaper
PE vs Historical
10.6 vs 11.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.5%
(market-implied from PE analysis)
1-Year Target
$73.22
(-2%)
2-Year Target
$72.12
(-3%)
3-Year Target
$71.04
(-4%)
3-Yr Target (if PE normalizes)
(PE: 11→11)
$74.12
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 9.7%)
$183.24
(+147%)
Base:
(SPY PE: 10.6, Growth: 9.7%)
$98.15
(+32%)
Bear:
(PE: 9.0, Growth: 9.7%)
$83.43
(+12%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 20.67 | Current EPS (TTM): $3.57
Bull Case
$158.84
(+114%)
Analyst growth 95.7%, PE expands to 22.7
Base Case
$144.40
(+94%)
Market implied 95.7%, PE stable at 20.7
Bear Case
$50.17
(-33%)
Severe decline -20.0%, PE contracts to 17.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.6 to 11.1
Stabilization Target:
$77.56
(+4.3%)
PE Expansion Potential:
+4.3%
Share & Embed Analysis
Last updated: October 22, 2026 11:33 PM ET
Data refreshes hourly during market hours. Next update: 12:33 AM
Data refreshes hourly during market hours. Next update: 12:33 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CBT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Specialty Chemicals Stocks
Top-rated stocks in Specialty Chemicals by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LIN
Linde plc Ordinary Shares |
STRONG BUY
29 analysts |
$544 | 41 HOLD |
|
ECL
Ecolab Inc |
STRONG BUY
24 analysts |
$325 | 48 HOLD |
|
SHW
Sherwin-Williams Co |
BUY
29 analysts |
$383 | 45 HOLD |
|
DD
Dupont De Nemours Inc |
STRONG BUY
18 analysts |
$165 | 72 BUY |
|
ALB
Albemarle Corp |
BUY
23 analysts |
$162 | 54 HOLD |
